---
title: "SHIJIA TECH: Net loss of 44.6086 million yuan in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253970103.md"
description: "SHIJIA TECH announced that its operating revenue in the first half of 2025 was 411 million yuan, a year-on-year decrease of 10.84%. The net loss was 44.6086 million yuan, compared to a net profit of 17.7976 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves"
datetime: "2025-08-21T10:46:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253970103.md)
  - [en](https://longbridge.com/en/news/253970103.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253970103.md)
generator: "portal-rs"
---

# SHIJIA TECH: Net loss of 44.6086 million yuan in the first half of 2025

SHIJIA TECH announced that its operating revenue in the first half of 2025 was 411 million yuan, a year-on-year decrease of 10.84%. The net loss was 44.6086 million yuan, compared to a net profit of 17.7976 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

### Related Stocks

- [002796.CN](https://longbridge.com/en/quote/002796.CN.md)

## Related News & Research

- [BofA says the coming jobs report is just an appetizer for the next Fed meeting](https://longbridge.com/en/news/297821819.md)
- [NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 Gene Replacement Product for MPS IIIB](https://longbridge.com/en/news/297947685.md)
- [VGP acquires 294,000 sq m land plot for VGP Park Oradea, Romania](https://longbridge.com/en/news/297616265.md)
- [BioVersys granted Fast-Track Designation from US FDA for BV100](https://longbridge.com/en/news/297734143.md)
- [Kitron plans new 8,850-sq-meter factory in Denmark’s Horsens amid growth push](https://longbridge.com/en/news/297664487.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**